In unconventional symptomatic AD, the transient suppression of the neuronal integrated stress response implemented concurrently with the long-term administration of the BACE1- and/or BACE2-activating drugs could be sufficient to stop the progression of the disease and to prevent its recurrence within the remaining lifetime of the treated patient. Here, BACE2 is linked to Alzheimer disease.